172 related articles for article (PubMed ID: 31765227)
1. The Effect of Oral Contraceptive Hormones on Anterior Cruciate Ligament Strength.
Konopka JA; Hsue L; Chang W; Thio T; Dragoo JL
Am J Sports Med; 2020 Jan; 48(1):85-92. PubMed ID: 31765227
[TBL] [Abstract][Full Text] [Related]
2. A prospective controlled study of the effect on blood pressure of contraceptive preparations containing different types and dosages of progestogen.
Wilson ES; Cruickshank J; McMaster M; Weir RJ
Br J Obstet Gynaecol; 1984 Dec; 91(12):1254-60. PubMed ID: 6440589
[TBL] [Abstract][Full Text] [Related]
3. [Influence of progestins on adverse effects of oral contraceptives].
Wynn V
Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
[TBL] [Abstract][Full Text] [Related]
4. The Intracellular Effect of Relaxin on Female Anterior Cruciate Ligament Cells.
Konopka JA; DeBaun MR; Chang W; Dragoo JL
Am J Sports Med; 2016 Sep; 44(9):2384-92. PubMed ID: 27245459
[TBL] [Abstract][Full Text] [Related]
5. A norgestimate-containing oral contraceptive: review of clinical studies.
Kafrissen ME
Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
[TBL] [Abstract][Full Text] [Related]
6. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
Notelovitz M; Kitchens CS; Khan FY
Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
[TBL] [Abstract][Full Text] [Related]
7. Effect of low-dose oral contraceptives on androgenic markers and acne.
Thorneycroft IH; Stanczyk FZ; Bradshaw KD; Ballagh SA; Nichols M; Weber ME
Contraception; 1999 Nov; 60(5):255-62. PubMed ID: 10717776
[TBL] [Abstract][Full Text] [Related]
8. Progestins and oral contraceptive-induced lipoprotein changes: a prospective study.
Lipson A; Stoy DB; LaRosa JC; Muesing RA; Cleary PA; Miller VT; Gilbert PR; Stadel B
Contraception; 1986 Aug; 34(2):121-34. PubMed ID: 3096633
[TBL] [Abstract][Full Text] [Related]
9. Rationale for new oral contraceptive dosing.
Williams JK
Int J Fertil Womens Med; 2004; 49(1):30-5. PubMed ID: 15038507
[TBL] [Abstract][Full Text] [Related]
10. A regimen of oral contraceptives restricted to the periovulatory period may permit folliculogenesis but inhibit ovulation.
Letterie GS
Contraception; 1998 Jan; 57(1):39-44. PubMed ID: 9554249
[TBL] [Abstract][Full Text] [Related]
11. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins.
Goldzieher JW; de la Peña A; Chenault CB; Cervantes A
Am J Obstet Gynecol; 1975 Jul; 122(5):625-36. PubMed ID: 1146928
[TBL] [Abstract][Full Text] [Related]
12. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins.
Wiegratz I; Jung-Hoffmann C; Kuhl H
Contraception; 1995 Jun; 51(6):341-6. PubMed ID: 7554973
[TBL] [Abstract][Full Text] [Related]
13. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive.
London RS; Chapdelaine A; Upmalis D; Olson W; Smith J
Acta Obstet Gynecol Scand Suppl; 1992; 156():9-14. PubMed ID: 1324557
[TBL] [Abstract][Full Text] [Related]
14. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency.
Knopp RH; Walden CE; Wahl PW; Hoover JJ; Warnick GR; Albers JJ; Ogilvie JT; Hazzard WR
J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796
[TBL] [Abstract][Full Text] [Related]
15. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
16. Studies on the role of intestinal bacteria in metabolism of synthetic and natural steroid hormones.
Adlercreutz H; Pulkkinen MO; Hämäläinen EK; Korpela JT
J Steroid Biochem; 1984 Jan; 20(1):217-29. PubMed ID: 6231418
[TBL] [Abstract][Full Text] [Related]
17. The effect of relaxin on the female anterior cruciate ligament: Analysis of mechanical properties in an animal model.
Dragoo JL; Padrez K; Workman R; Lindsey DP
Knee; 2009 Jan; 16(1):69-72. PubMed ID: 18964043
[TBL] [Abstract][Full Text] [Related]
18. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
[TBL] [Abstract][Full Text] [Related]
19. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
[TBL] [Abstract][Full Text] [Related]
20. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel.
Gaspard UJ; Buret J; Gillain D; Romus MA; Lambotte R
Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
